Axxam S.p.A. announces a collaboration with Vivozon Inc. with the aim to support Vivozon in the development of innovative small molecule drugs for the treatment of patients with unmet CNS medical needs.
Thanks to its expertise in early phase discovery biology, Axxam began the collaboration with Vivozon by providing access to a panel of cell-based assays to test Vivozon’s compounds on targets of interest, thereby supporting Vivozon’s scientists in the hit-to-lead program and drug discovery research.
Dr. Stefan Lohmer, Co-founder & Chief Executive Officer of Axxam, commented, “We are extremely pleased with the collaboration we have established with Vivozon over the past few years and we are looking forward to continuing and expanding it in the future. We are excited that Vivozon is our first client based in the Republic of Korea, which is consistently ranked as one of the top innovative countries in the world”.
Dr. Doo Lee, Co-founder & Chief Executive Officer of Vivozon, added, “We are grateful to have Axxam as our partner, and greatly appreciate their support and commitment in helping us make progress with the discovery of innovative CNS drugs by providing top-quality services. We believe that more Korean companies will collaborate with Axxam in the drug discovery field”.
For more information: www.axxam.com